Program Summary: This presentation provides an overview of the role of BRCA1 and BRCA2 genes in the development of ovarian cancer and national recommendations regarding testing for BRCA mutations. Details regarding how results of BRCA genetic testing can be used for predictive, predispositional, and prognostic information will be shared, including recommendations for tailoring treatment options based on test results. Processes and methods for BRCA genetic testing will be presented, including a discussion of roles for oncology nurses.
- Discuss the clinical significance of germline and somatic testing for BRCA1 and/or BRCA2 in ovarian cancer
- Understand evolving paradigms for BRCA testing in ovarian cancer
This program is intended for US healthcare professionals only.
AstraZeneca will comply with any and all federal or state reporting requirements regarding any value or expense
associated with this event.
AstraZeneca fully supports and abides by the PhRMA Code on Interactions With Health Care Professionals (HCPs). This program is open only to HCP invitees. AstraZeneca will not accommodate attendance of a spouse or other guest of any HCP attendee, nor will AstraZeneca pay for transportation or parking costs of attendees. If you are a prescriber and/or a Federal, State, or institution employee, you may be subject to laws, regulations, or rules that prohibit or limit your receipt of gifts, meals, or items of value. We ask that you comply with any such restrictions. AstraZeneca will not recommend, endorse, or support the submission of this promotional program for CE credits. AstraZeneca will comply with any and all federal or state reporting requirements regarding any value or expense associated with this event.